Ayurvedic Herbs Market Growth is Projected to Reach $21.6 Billion by 2028
The global Ayurvedic herbs market size was valued at $9.5 billion in 2020 and is anticipated to reach $21.6 billion by 2028, with a CAGR of 10.8% during the forecast period. The market is expected to exhibit an incremental revenue opportunity of $12 billion from 2020 to 2028. The Ayurvedic herbs market growth is propelled by rise in consumer health consciousness and improved distribution network. Consumers are prepared to pay more for those products that provide health advantages, and this awareness is expected to be a driver for the Ayurvedic herbs products market development. Ayurvedic Herbs and its products are still in nascent stages in various western countries such as Argentina, Canada, and Peru along with other developing regions. These are still untapped, which present lucrative Ayurvedic herbs market opportunities for manufacturers of Ayurvedic herbs products.
Get a Sample PDF Report to understand our report before you
purchase: https://www.alliedmarketresearch.com/request-sample/A11994
The key players profiled in this report include are
Colgate-Palmolive Company, Dabur India Ltd., Emami Limited, Kairali Ayurvedic
Group, P&G, Patanjali Ayurved Limited, Shahnaz Ayurveda Pvt. Ltd, Shree
Baidyanath Ayurveda Bhawan Pvt. Ltd, The Himalaya Drug Company, and Unilever.
Growing attention to alternative medicine is creating
opportunities and Ayurvedic herbs market trends for the natural ingredients in
coming years. There is an opportunity for suppliers of natural ingredients in
developing countries, especially since some ingredients are not grown in
Europe. Turmeric, for example, is indigenous to South Asia and is now finding
applications in supplements and in medical products. Like turmeric, many other
botanicals and essential oils used in natural health products simply cannot be
grown in Europe.
According to the Ayurvedic Herbs market analysis, the market
is segmented on the basis of herb type, form, disease indication, distribution
channel, and region. Based on herb type, the market is categorized into
Withania Somnifera (Ashwagandha), Frankincense (Boswellia), Indian Gooseberry
(Triphala), Bacopa Monnieri (Brahmi), Turmeric, Cumin, Bitter Melon, Others.
Withania Somnifera (Ashwagandha) are widely used globally
and is one of the prime herb types for Ayurvedic herbs; thus, is expected to
influence the overall Ayurvedic herbs industry. The Withania Somnifera segment
was valued at $2.3 billion and is expected to grow with a CAGR of 10% from 2021
to 2028, to reach $5.0 billion by 2028.
Buy Now and Get Discount Up to 50% https://www.alliedmarketresearch.com/ayurvedic-herbs-market/purchase-options
By form, the capsules/tablets segment held a major Ayurvedic
herbs market share in 2020, and is expected to remain dominant throughout the
forecast period. This is due to the rise in consumer demand for healthy and
clean-label herbal products.
Based on disease indication, the skin diseases segment held
a major share of the Ayurvedic herbs market in 2020. This is attributed to rise
in spending on Ayurvedic products herbs for the treatment of the skin.
The business to consumer channel including the
hypermarkets/supermarkets segment was the leading channel with maximum share in
2020, growing with significant CAGR during the Ayurvedic herbs market forecast
period. This is attributed to increase in business of retail sales in different
regions and availability of large shelf space for maximum sales.
Region wise, Asia-Pacific was the prominent region in 2020,
garnering maximum share in the Ayurvedic herbs market, owing to huge consumer
base and increase in population. Moreover, the region hold the major share
owing to rich tradition of herbal medicine led by India, Sri Lanka, Pakistan,
Indonesia, among others.
To Ask About Report Availability or Customization, Click
Here: https://www.alliedmarketresearch.com/connect-to-analyst/A11994
Key findings of the study
- Based
on herb type, The Withania Somnifera segment was valued at $2.3 billion
and is expected to grow with a CAGR of 10% from 2021 to 2028, to reach
$5.0 billion by 2028.
- Based
on form, Extracts segment witness a major annual growth rate of 10.9%.
- Based
on disease indication, the skin diseases held the major share and is
expected to remain dominant throughout the forecast period.
- Based
on distribution channel, Business to consumer held the major share of
64.9% in 2020.
Comments
Post a Comment